Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is to see if combining bevacizumab with docetaxel works in treating women
who have locally advanced or metastatic breast cancer. Drugs used in chemotherapy work in
different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal
antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the
ability of cancer cells to grow and spread. Others find cancer cells and help kill them or
deliver cancer-killing substances to them. Combining chemotherapy with monoclonal antibody
therapy may kill more tumor cells.